Myelofibrosis: A concise review of clinical and pathologic features and treatment

✍ Scribed by Dr. Roy E. Smith; Mark K. Chelmowski; Edward J. Szabo

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: English
• Weight: 665 KB
• Volume: 29
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/ajh.2830290311

✦ Synopsis

This paper reviews and clarifies the current understanding of the clinical and pathologic features and treatment of MF. Recent investigations indicate that MF may be mediated by platelet-and megakaryocyte-derived growth factors, impaired prostaglandin-mediated stem cell growth inhibition, or excessive endothelial cell and fibroblast proliferation. Immunologic disorders have been associated with MF. MF may be either a primary or a secondary phenomenon. Secondary MF often regresses with appropriate treatment of this underlying disorder. Primary MF may require androgen therapy, splenectomy, splenic irradiation, bone curettage, chemotherapy, or bone marrow transplantation.